journal article·2025-02Open access

Highly Efficient and Universal Degradation of PD‐L1 via Mitochondrial Oxidative Stress Evoked by Cationic AIE‐Active Photosensitizers for Cancer Immunotherapy

Jiazhe Liu, Ruoyao Zhang, Yixuan Bao, Yijun Chen, Wenfang Zheng, Jianing Yuan, Zhuomiao Zhang, Pu Chen, Meiju Ji, Yangyang Cheng, Peng Hou, Dongfeng Dang, Dan Ding, Chao Chen

Advanced Functional Materials· Volume 35· Issue 7

Abstract

Abstract The blockade of interactions between programmed death‐ligand 1 (PD‐L1) on cancer cell surfaces and programmed cell death‐1 (PD‐1) receptors on T cells is a crucial strategy in cancer immunotherapy. However, the continuous replenishment of PD‐L1 from intracellular stores presents a significant challenge that undermines therapeutic efficacy. Therefore, effective downregulation of intracellular PD‐L1 is essential for improving treatment outcomes. In this study, a novel approach that utilizes mitochondrial oxidative stress to achieve highly efficient and universal PD‐L1 degradation is presented. A cationic aggregation‐induced emission‐active photosensitizer, DPA‐B‐YP+, which generates reactive oxygen species (ROS) upon light activation to induce mitochondrial oxidative stress on demand is developed. Compared to traditional high‐performance PD‐L1 degraders such as metformin and berberine, ROS‐induced mitochondrial stress by DPA‐B‐YP+ demonstrates superior efficiency and broader applicability in PD‐L1 degradation across various tumor types. Mechanistic studies reveal that PD‐L1 degradation by DPA‐B‐YP+ occurs via the AMPK‐ubiquitination pathway. Furthermore, in a murine immunogenic “cold” tumor model, DPA‐B‐YP+ effectively degrades PD‐L1 and significantly enhances CD8+ T cell‐mediated immune responses upon light activation, without the need for additional drugs or immune adjuvants. These findings present a novel approach and material for PD‐L1 degradation, contributing to advancements in cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Endocrinology International Joint Research Center for Tumor Precision Medicine of Shaanxi Province The First Affiliated Hospital of Xi'an Jiaotong University Xi'an 710061 P.R. China

School of Medical Technology Institute of Engineering Medicine Beijing Key Laboratory for Separation and Analysis in Biomedicine and Pharmaceuticals Beijing Institute of Technology Beijing 100081 China

Center for Translational Medicine The First Affiliated Hospital of Xi'an Jiaotong University Xi'an 710061 China

School of Chemistry Xi'an Jiaotong University Xi'an 710049 China

Frontiers Science Center for Cell Responses State Key Laboratory of Medicinal Chemical Biology Key Laboratory of Bioactive Materials Ministry of Education, and College of Life Sciences Nankai University Tianjin 300071 China

Funding

National Natural Science Foundation of China

References (74)

Show source-provided references
1. 10.1136/jclinpath-2017-20485310.1136/jclinpath-2017-204853 ↗
2. 10.1172/JCI8001110.1172/JCI80011 ↗
3. 10.1002/agt2.54510.1002/agt2.545 ↗
4. 10.1038/s41590-024-01789-x10.1038/s41590-024-01789-x ↗
5. 10.1038/s41551-019-0375-610.1038/s41551-019-0375-6 ↗
6. 10.1002/adma.20220612110.1002/adma.202206121 ↗
7. 10.1038/s41392-018-0022-910.1038/s41392-018-0022-9 ↗
8. 10.1126/sciadv.abh214810.1126/sciadv.abh2148 ↗
9. 10.1016/j.celrep.2024.11371210.1016/j.celrep.2024.113712 ↗
10. 10.1002/advs.20230317510.1002/advs.202303175 ↗
11. 10.1038/s41419-020-03140-210.1038/s41419-020-03140-2 ↗
12. 10.1126/sciadv.ade994410.1126/sciadv.ade9944 ↗
13. 10.1016/j.ejmech.2024.11626710.1016/j.ejmech.2024.116267 ↗
14. 10.1681/ASN.200601008310.1681/ASN.2006010083 ↗
15. 10.1038/s41418-020-00700-z10.1038/s41418-020-00700-z ↗
16. 10.1210/me.2014-118010.1210/me.2014-1180 ↗
17. 10.1016/j.molcel.2018.07.03010.1016/j.molcel.2018.07.030 ↗
18. 10.1073/pnas.211485111910.1073/pnas.2114851119 ↗
19. 10.1016/j.intimp.2023.11090510.1016/j.intimp.2023.110905 ↗
20. 10.1016/j.phymed.2023.15531810.1016/j.phymed.2023.155318 ↗
21. 10.1016/j.molcel.2021.03.03710.1016/j.molcel.2021.03.037 ↗
22. 10.1016/j.cub.2014.03.03410.1016/j.cub.2014.03.034 ↗
23. 10.31635/ccschem.021.20210121710.31635/ccschem.021.202101217 ↗
24. 10.1038/s41581-023-00775-010.1038/s41581-023-00775-0 ↗
25. 10.1038/s41401-020-0366-x10.1038/s41401-020-0366-x ↗
26. 10.1016/S0304-3835(02)00006-X10.1016/S0304-3835(02)00006-X ↗
27. 10.1016/j.febslet.2014.07.02510.1016/j.febslet.2014.07.025 ↗
28. 10.1016/j.freeradbiomed.2009.02.01910.1016/j.freeradbiomed.2009.02.019 ↗
29. 10.1074/jbc.RA118.00257910.1074/jbc.RA118.002579 ↗
30. 10.1038/nrm.2017.9510.1038/nrm.2017.95 ↗
31. 10.1002/agt2.35210.1002/agt2.352 ↗
32. 10.1002/agt2.36410.1002/agt2.364 ↗
33. 10.1002/adma.20190491410.1002/adma.201904914 ↗
34. 10.1021/accountsmr.2c0003910.1021/accountsmr.2c00039 ↗
35. 10.1021/acs.chemrev.1c0038110.1021/acs.chemrev.1c00381 ↗
36. 10.1039/D2SC00067A10.1039/D2SC00067A ↗
37. 10.1021/ja310324q10.1021/ja310324q ↗
38. 10.1002/adma.20180135010.1002/adma.201801350 ↗
39. 10.1039/C6SC04947H10.1039/C6SC04947H ↗
40. 10.1002/advs.20190276010.1002/advs.201902760 ↗
41. 10.1016/j.mser.2021.10064910.1016/j.mser.2021.100649 ↗
42. 10.1002/adma.20220952910.1002/adma.202209529 ↗
43. 10.1039/D0CS00173B10.1039/D0CS00173B ↗
44. 10.1038/s41571-020-0410-210.1038/s41571-020-0410-2 ↗
45. 10.1002/anie.20180524610.1002/anie.201805246 ↗
46. 10.1002/adma.20200266110.1002/adma.202002661 ↗
47. 10.1016/j.ccr.2022.21481810.1016/j.ccr.2022.214818 ↗
48. 10.1002/adma.20190353010.1002/adma.201903530 ↗
49. 10.1002/anie.20241180210.1002/anie.202411802 ↗
50. Kim H. · J. Visualized Exp. · 2020 · 23
51. 10.1038/s41565-023-01476-210.1038/s41565-023-01476-2 ↗
52. 10.1021/jacs.8b0865810.1021/jacs.8b08658 ↗
53. 10.1002/adfm.20241020210.1002/adfm.202410202 ↗
54. 10.1016/0076-6879(95)60154-610.1016/0076-6879(95)60154-6 ↗
55. 10.1002/adma.20180482710.1002/adma.201804827 ↗
56. 10.1002/anie.20150622510.1002/anie.201506225 ↗
57. 10.1021/acs.nanolett.8b0107110.1021/acs.nanolett.8b01071 ↗
58. Yu C. Y. · Adv. Mater. · 2017 · 29
59. 10.1002/adfm.20200714910.1002/adfm.202007149 ↗
60. 10.1016/j.apsb.2020.06.01410.1016/j.apsb.2020.06.014 ↗
61. 10.1002/adma.20200020810.1002/adma.202000208 ↗
62. 10.1016/j.xcrm.2023.10135710.1016/j.xcrm.2023.101357 ↗
63. 10.1016/j.canlet.2023.21651010.1016/j.canlet.2023.216510 ↗
64. 10.1126/sciadv.abq465910.1126/sciadv.abq4659 ↗
65. 10.1002/adma.20230536110.1002/adma.202305361 ↗
66. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
67. 10.1016/j.matt.2022.04.03210.1016/j.matt.2022.04.032 ↗
68. 10.1038/s41551-018-0262-610.1038/s41551-018-0262-6 ↗
69. 10.1002/adma.20200791010.1002/adma.202007910 ↗
70. 10.1038/s41563-024-01825-z10.1038/s41563-024-01825-z ↗
71. 10.1038/s41551-024-01191-w10.1038/s41551-024-01191-w ↗
72. 10.1158/1078-0432.CCR-13-220010.1158/1078-0432.CCR-13-2200 ↗
73. 10.1038/s41591-024-02805-110.1038/s41591-024-02805-1 ↗
74. 10.1007/s12020-022-03202-910.1007/s12020-022-03202-9 ↗